MedPath

A Phase 2 study to evaluate the efficacy and safety of T-817MA in patients with Alzheimer's Disease.

Phase 2
Conditions
Alzheimer's Disease
Registration Number
JPRN-jRCT2080222449
Lead Sponsor
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients, whose age is between 55 and 90, taking donepezil hydrochloride, and diagnosed as mild to moderate Alzheimer's Disease according to the diagnostic criteria

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy, Safety
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath